Seattle Genetics Appoints John A. Orwin To Board Of Directors

Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that John A. Orwin has been appointed to the company’s Board of Directors. Mr. Orwin is a biotechnology and pharmaceutical industry veteran with nearly 25 years of experience, including senior leadership positions in many commercial oncology organizations. He currently serves as Chief Executive Officer of Relypsa, a clinical-stage pharmaceutical company.

“John’s deep background in sales and marketing operations, as well as his experience in executive leadership positions at public biopharmaceutical companies will provide a strong addition to our Board,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. “I look forward to his contributions as we continue to deliver on Seattle Genetics’ strategic priorities, including making ADCETRIS ® (brentuximab vedotin) available to patients in its approved indications, broadly evaluating ADCETRIS across a range of CD30-positive malignancies and advancing our pipeline of other antibody-drug conjugates (ADCs).”

Mr. Orwin commented, “Seattle Genetics has delivered exceptionally well on the commercialization of ADCETRIS following its U.S. approval in 2011, and through the significant ongoing clinical development activities to broaden its labeled indications. In addition, under the collaboration with Takeda, ADCETRIS has become an important global brand. I am pleased to be joining the Board and look forward to working with the team to deliver on its goal of improving the lives of people with cancer.”

John Orwin has served as Chief Executive Officer of Relypsa, Inc. since June 2013. Prior to Relypsa, he was at Affymax, serving most recently as Chief Executive Officer and a member of the Board of Directors. Previously, Mr. Orwin was Vice President and then Senior Vice President of the BioOncology Business Unit at Genentech (now a member of the Roche Group), where he was responsible for all marketing, sales, business unit operations and pipeline brand management for Genentech’s oncology portfolio in the United States. He has also held senior marketing and sales positions at Johnson & Johnson, Alza Pharmaceuticals, Sangstat Medical Corporation, Rhone-Poulenc Rorer Pharmaceuticals and Schering-Plough Corporation. Mr. Orwin received an M.B.A. from New York University and a B.A. from Rutgers University.

If you liked this article you might like

Biotech Leaders Join Corporate Chorus Angry Over Trump's DACA Move

Valeant Higher on Paulson Stake Increase; ImmunoGen Pops; Seattle Genetics Perplexes: Biotech Movers

Biotech Movers: Clovis, Seattle Genetics, Rigel

Apple Could Explode Higher to $200 a Share If This Chart Pattern Is Correct

Analysts' Actions -- Costco, J.C. Penney, Cisco, TherapeuticsMD and More